Cellectis SA (CLLS) AI Stock Analysis

• Market Cap: $229.65M
• Dividend Yield: N/A
• Average Volume (3M): 88.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.12
• Revenue Growth: 334.10%
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 72,093,636
• 10 Day Avg. Volume: 101,085
• 30 Day Avg. Volume: 88,984
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 1.22
• Enterprise Value/Gross Profit: 1.77
• Enterprise Value/Ebitda: -1.93
• 1Y Price Target: $2.50
• Price Target Upside: -20.89% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 64 Neutral
• Price Target: $3.00 ▼(-5.06% Downside)

Cellectis SA's overall stock score is driven by positive technical momentum and encouraging earnings call sentiment, particularly regarding clinical trial progress and strategic partnerships. However, financial performance challenges and valuation uncertainties due to ongoing losses weigh on the score.

Positive Factors

Strategic Partnerships

Partnerships with major pharmaceutical companies like AstraZeneca enhance Cellectis' R&D capabilities and market reach, supporting long-term growth.

Clinical Trial Progress

Advancing to Phase II trials reflects promising clinical progress, potentially leading to new product approvals and revenue streams.

Cash Position

A strong cash position ensures financial stability and supports ongoing R&D and clinical trials, crucial for future growth.

Negative Factors

Profitability Challenges

Persistent losses and negative profit margins highlight operational inefficiencies, which could hinder long-term financial sustainability.

Revenue Consistency

Inconsistent revenue growth poses risks to financial stability and may affect the company's ability to invest in R&D and expansion.

Arbitration Uncertainty

Legal disputes can lead to financial liabilities and distract management, potentially impacting strategic focus and resource allocation.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis SA (CLLS) is a biotechnology company focused on developing innovative gene-editing technologies for the treatment of cancer and other genetic diseases. Founded in 1999 and headquartered in Paris, France, Cellectis specializes in engineered CAR T-cell therapies and gene-editing technologies, primarily utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) platform. The company's core products and services are directed towards creating breakthrough therapies that can modify genes and enhance the immune response against tumors, with a strong emphasis on personalized medicine.

How the Company Makes Money

Cellectis generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. The company primarily earns money by entering into strategic alliances that provide funding for research and development in exchange for rights to commercialize its gene-editing technologies and products. Additionally, Cellectis may receive milestone payments and royalties based on the commercial success of therapies developed using its technologies. Significant partnerships with major players in the pharmaceutical industry contribute to its revenue streams, as well as potential advancements in clinical trials that lead to further business opportunities.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA shows mixed financial health with stable liquidity and cash management but ongoing challenges in profitability and revenue consistency. The balance sheet indicates a stable but declining equity position, while cash flow improvements provide a positive outlook amid persistent net losses.

Income Statement

The company shows a fluctuating revenue trend, with a significant decline from 2021 to 2023, followed by a recovery in 2024 and TTM. Gross profit margin is relatively stable but net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. The equity ratio has been declining, which might indicate increasing liabilities relative to assets. Despite this, the company maintains a solid cash position, which can be advantageous for liquidity.

Cash Flow

Positive developments in cash flow are noted, with operating cash flow turning positive in recent periods. The free cash flow growth is encouraging, although the company has historically faced negative free cash flows. The ratio of operating cash flow to net income is favorable, highlighting efficient cash management despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.51M	41.51M	755.00K	19.17M	73.95M	73.95M
Gross Profit	38.86M	21.63M	18.00K	17.40M	37.67M	37.67M
EBITDA	-35.61M	-15.84M	-92.64M	-76.38M	-86.46M	-34.68M
Net Income	-59.30M	-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet
Total Assets	353.97M	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	198.15M	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	113.83M	91.46M	92.85M	82.85M	102.24M	111.30M
Total Liabilities	256.86M	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	97.11M	131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow
Free Cash Flow	-25.98M	19.15M	-25.82M	-89.89M	-124.31M	-126.52M
Operating Cash Flow	-23.04M	22.99M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	9.89M	-102.81M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	-5.38M	89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 3.16 is above the 20-day moving average (MA) of 2.84, above the 50-day MA of 2.63, and above the 200-day MA of 1.79, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 71.01 is Negative, neither overbought nor oversold. The STOCH value of 74.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	64 Neutral	$229.65M	―	-48.36%	―	334.10%	―
FDMT	52 Neutral	311.04M	-1.91	-31.51%	―	0.00%	0.00%
CRBU	52 Neutral	160.17M	-1.00	-58.95%	―	-72.45%	-28.60%
EDIT	51 Neutral	244.58M	-1.05	-176.57%	―	-41.97%	-20.86%
NKTX	39 Underperform	135.66M	-1.34	0.00%	―	0.00%	26.33%
VOR	33 Underperform	192.56M	-0.11	0.00%	―	0.00%	-686.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cellectis SA Corporate Events

Cellectis S.A. Reports Interim Financial Results for First Half of 2025

Cellectis S.A. released its interim financial report for the six-month period ending June 30, 2025, showcasing its financial position and performance. The report highlights a significant increase in non-current financial assets and other non-current assets, reflecting the company’s strategic investments and growth. This financial update provides stakeholders with insights into Cellectis’s operational progress and its positioning within the biotechnology industry.

Cellectis Reports Q2 2025 Financials and Key Clinical Milestones

Cellectis S.A. announced its second-quarter 2025 financial results and business updates, highlighting key developments in its clinical programs and strategic partnerships. The company completed end-of-Phase 1 meetings with the FDA and EMA for its UCART22 therapy in relapsed or refractory B-cell acute lymphoblastic leukemia, paving the way for a pivotal Phase 2 trial in the second half of 2025. Additionally, Cellectis is advancing its collaboration with AstraZeneca and expects significant milestones in its ongoing clinical trials, including a Phase 1 readout for UCART20x22 in late 2025. Financially, Cellectis reported $230 million in cash and equivalents as of June 30, 2025, providing a runway into the second half of 2027.

Cellectis to Announce Q2 2025 Financial Results on August 4

On July 28, 2025, Cellectis announced it will release its second-quarter financial results for 2025 on August 4, 2025, after the US market closes. The announcement will be followed by an investor conference call and webcast on August 5, 2025, which will cover the company’s financial performance and business updates. This event is significant for stakeholders as it provides insights into Cellectis’ operational progress and strategic direction in the biotechnology sector.

Cellectis S.A. Announces Board Changes and Strategic Appointments

On June 26, 2025, Cellectis S.A. held its Combined General Meeting of Shareholders, where significant changes to the Board of Directors were announced. André Muller was appointed as a new director, while the terms of Axel-Sven Malkomes expired, and Pierre Bastid’s resignation took effect. Additionally, Muller, along with Donald Bergstrom and Rainer Boehm, was appointed to the Audit Committee, all being independent members. These changes are part of the company’s strategic adjustments to strengthen its governance and operational oversight, potentially impacting its market positioning and stakeholder relations.

Cellectis Announces Board Changes Following Shareholders’ Meeting

On June 26, 2025, Cellectis held a shareholders’ meeting where approximately 57% of voting rights were exercised. The meeting resulted in the adoption of most resolutions and the appointment of Mr. André Muller to the Board of Directors, while Mr. Axel-Sven Malkomes’ term expired, and Mr. Pierre Bastid’s resignation became effective. The changes in the board are expected to bring valuable expertise to Cellectis, enhancing its strategic direction and operations in the biotechnology sector.